RemeGen Co

RemeGen Co Financing Cash Flow

The Net Financing Cash Flow of RemeGen Co (688331.SS) as of Oct 26, 2026 is 551.96 M CNY. In the previous year, Net Financing Cash Flow was 1.39 B CNY — a change of -60.38% (lower).

Financing Cash Flow

551.96 MCNY

YoY

-60.38%

Last updated:

Net Financing Cash Flow of RemeGen Co is 2025 551.96 M CNY. Net Financing Cash Flow of RemeGen Co was 2024 1.39 B CNY. It decreases by -60.38% lower compared to the previous year.

The RemeGen Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
206.29 M CNY
Jan 1, 2019
407.32 M CNY
Jan 1, 2020
3.90 B CNY
Jan 1, 2021
-626.90 M CNY
Jan 1, 2022
2.43 B CNY
Jan 1, 2023
978.31 M CNY
Jan 1, 2024
1.39 B CNY
Jan 1, 2025
551.96 M CNY
The RemeGen Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
551.96 MCNY-60.38%
1.39 BCNY+42.39%
978.31 MCNY-59.69%
2.43 BCNY-487.14%
-626.90 MCNY-116.06%
3.90 BCNY+858.51%
407.32 MCNY+97.45%
206.29 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

Net Financing Cash Flow of RemeGen Co is 551.96 M CNY in 2025.

Net Financing Cash Flow of RemeGen Co changed from 1.39 B CNY to 551.96 M CNY, representing a -60.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's RemeGen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — RemeGen Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — RemeGen Co